Trent P. Munro - Nanotechnology

Author Information

Trent P. Munro is affiliated with the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, St Lucia, Queensland 4072, Australia. With a robust background in bioengineering and nanotechnology, Trent P. Munro has made significant contributions to his field, particularly focusing on biomedical applications and translational sciences.

Research Contributions

Trent P. Munro has authored numerous influential papers, contributing significantly to various research areas including apoptosis resistance in CHO cells, COVID-19 pandemic response, inflammasome activation in human microglia, and long noncoding RNA therapies. His recent work spans from bioprocessing applications in Chinese Hamster Ovary cells to the development of SARS-CoV-2 vaccines and identification of ovarian cancer biomarkers. Notably, his research has been pivotal in advancing the understanding and development of molecular clamp-stabilised subunit vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Aliases

Trent P. Munro is also known by various aliases including Trent Munro, Trent P. Munro, Trentp. Munro, and T Munro.

Publication and Citation Metrics

Metric	Value
Citation Count	2376
h-index	29
Paper Count	93

Publications:

Modelling Apoptosis Resistance in CHO cells with CRISPR-Mediated Knock-outs of Bak1, Bax, and Bok.

DOI: 10.1002/bit.28062

Year: 2022

A call to action for translational sciences in COVID-19 and future pandemics.

DOI: 10.1038/d41573-022-00020-6

Year: 2022

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction

DOI: 10.1101/2022.01.11.475947

Year: 2022

The potential of long noncoding RNA therapies.

DOI: 10.1016/j.tips.2022.01.008

Year: 2022

Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications.

DOI: 10.1080/07388551.2021.1998821

Year: 2021

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

DOI: 10.1016/S1473-3099(21)00200-0

Year: 2021

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

DOI: 10.1002/cti2.1269

Year: 2021

Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.

DOI: 10.1021/acs.molpharmaceut.1c00401

Year: 2021

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

DOI: 10.2139/SSRN.3769210

Year: 2021

Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine

DOI: 10.1016/j.tibtech.2020.06.004

Year: 2020

What are Coherent States?

What Role Do Biosensors Play?

How Do Nanoparticles Work in Odor Control?

How Do Nanoparticles Generate Heat?

Why Do These Properties Change at the Nanoscale?

What is Zeta Potential?

What are some global collaborations in Nanotechnology?

What Are the Advantages of Nanotechnology in Water Purification?

What is Nanotechnology and How Does it Relate to Glass?

Why is Chemical Potential Important in Nanotechnology?

Partnered Content Networks

Relevant Topics